The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.
A user with high pre-finasteride estrogen levels is asking if they need to normalize their hormone levels before starting finasteride and whether they should postpone dermarolling until they begin finasteride. The user is 21.5 years old.
The user reports positive results from using finasteride for six months, noticing hair regrowth despite ongoing shedding and dry scalp issues. They suspect hard water and a possible vitamin D deficiency may also affect their hair condition.
The user experienced heart palpitations from using Fin (0.1%) and Min (10%) and is seeking alternatives. Options suggested include PRP or Mesotherapy, with a recommendation to try topical Fin without Min.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
The user is updating on their hair loss treatment progress after 4 months using oral finasteride, topical minoxidil spray, and weekly 1mm dermarolling. The crown area is slowly improving, with a smaller bald spot radius compared to the previous month.
A user in Indonesia is seeking legitimate RU58841 due to local availability issues and considers using Ubuy for international shipping. Another user suggests checking seller ratings and product details on Ubuy and mentions that specialized forums or international suppliers might also be helpful.
The user had a failed hair transplant in 2018, didn't use medication, and experienced severe depression from further hair loss. They started treatment in 2022 with 0.5mg daily finasteride, 2.5mg oral minoxidil, 1ml daily topical minoxidil, and are considering low dose RU58841 and dermarolling.
The conversation is about whether Saw Palmetto, which has similar but less potent effects to Finasteride, could cause the same side effects due to lowering DHT levels. The user is considering oral Saw Palmetto as an alternative to Finasteride for hair loss treatment.
The conversation discusses the anticipated release of GT20029, with some users expressing skepticism about its availability. It also mentions the use of treatments like Minoxidil, finasteride, RU58841, and dutasteride for hair loss.
A user shared their experience on day 9 after a hair transplant, mentioning the use of vitamin E oil and conditioner to remove scabs. They received positive feedback on their progress and were advised to be patient for noticeable results in a few months.
The user is experiencing hair shedding after using a multipeptide hair growth serum and is concerned about losing baby hair. They are questioning whether they should stop using the serum due to this shedding.
A 34-year-old male shares a nine-month update on hair loss treatment using 1.25mg oral finasteride daily, 5% topical minoxidil 5-7 times a week, and 1% ketoconazole shampoo twice a week. He reports stopping diffuse thinning and regaining crown density, though his hairline may require a transplant.
Switching from finasteride to a generic dutasteride led to unexpectedly high DHT levels, prompting a switch to a reputed brand and consideration of softgel capsules for better absorption. The user plans to retest DHT levels and may return to finasteride if issues persist.
The conversation discusses the potential risks and considerations of purchasing raw Clascoterone powder from Made-In-China to create a DIY topical solution for hair loss. Concerns include fake products, low purity, and contamination, with a request for experiences and advice on reliable suppliers.
Seborrheic dermatitis can cause hair loss, and treatments like ketoconazole shampoo, topical steroids, and oral antifungals may help. Some consider using finasteride and minoxidil for hair loss despite dermatitis.
PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.
The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.
The user is exploring topical Saw Palmetto as a milder alternative to microdosing topical Finasteride for hair loss, aiming to minimize systemic DHT impact. They plan to experiment with this herbal remedy for a year to assess its effectiveness on their mild androgenetic alopecia without significant side effects.
The user shared 9-month results using a 4-in-1 spray containing finasteride, minoxidil, ketoconazole, and biotin, along with lifestyle changes like jogging, quitting smoking, and using collagen supplements. They also incorporated dermastamping, dermarolling, and various oils into their routine, reporting positive hair regrowth.
People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.
Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.
The user reported positive feedback on hair appearance after switching from topical to oral minoxidil and finasteride, with no side effects. The treatment includes 1.1mg finasteride, 3mg minoxidil, biotin, and vitamins B5, B6, and C daily.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The conversation is about hair loss treatments. The user considers using a foam with Saw palmetto, caffeine, and EGCG, but another user suggests just using finasteride.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
A user noticed watery semen and decreased volume after a week of using finasteride and asked if taking Zinc, pygeum, and lecithin supplements would affect finasteride's effectiveness. The conversation is about the side effects of finasteride and potential supplements to counteract them.
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
User sshamu's progress pictures of 4 months using minoxidil foam and 1MM dermarolling for hair loss, which resulted in impressive results. There is also discussion about how often to use the treatments, as well as potential side effects of finasteride.
The user reported 4 months of using 0.5mg finasteride and 6 months of microneedling, Nizoral, and topical melatonin. They saw improvement on the left side but no improvement on the right side and are hesitant to start minoxidil.